Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

Novo Nordisk's acquisition of Akero Therapeutics for up to $5.2 billion marks a significant move in the pharmaceutical industry. Shareholders of Akero will initially receive $54 per share, with an additional $6 contingent on the approval of the EFX drug by 2031. This deal highlights Novo Nordisk's commitment to expanding its portfolio and investing in innovative treatments, which could lead to advancements in patient care and increased market competitiveness.